A multicentre verification study of the QuantiFERON (R)-TB Gold Plus assay

E. D. Pieterman; F. G. Liqui Lung; A. Verbon; H. I. Bax; C. W. Ang; J. Berkhout; G. Blaauw; A. Brandenburg; N. D. van Burgel; A. Claessen; K. van Dijk; M. Heron; M. Hooghiemstra; R. Leussenkamp-Hummelink; E. van Lochem; I. H. M. van Loo; B. Mulder; A. Ott; O. Pontesilli; A. Reuwer; P. Rombouts; V. Saegeman; M. Scholing; S. Vainio; J. E. M. de Steenwinkel

doi:10.1016/j.tube.2017.11.014

A multicentre verification study of the QuantiFERON (R)-TB Gold Plus assay

E. D. Pieterman^*, F. G. Liqui Lung, A. Verbon, H. I. Bax, C. W. Ang, J. Berkhout, G. Blaauw, A. Brandenburg, N. D. van Burgel, A. Claessen, K. van Dijk, M. Heron, M. Hooghiemstra, R. Leussenkamp-Hummelink, E. van Lochem, I. H. M. van Loo, B. Mulder, A. Ott, O. Pontesilli, A. ReuwerP. Rombouts, V. Saegeman, M. Scholing, S. Vainio, J. E. M. de Steenwinkel

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objectives: The aim of this verification study was to compare the QuantiFERON (R)-TB Gold Plus (QFT-Plus) to the QuantiFERON (R)-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8(+) T-cell response above the CD4(+) T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods: Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of > 0.6 IU/mL interferon-gamma release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8(+) T-cell response. Results: Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-gamma release compared to all other subjects (p = 0.029). Conclusion: Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-gamma release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.

Original language	English
Pages (from-to)	136-142
Number of pages	7
Journal	Tuberculosis
Volume	108
DOIs	https://doi.org/10.1016/j.tube.2017.11.014
Publication status	Published - 1 Jan 2018

Keywords

Tuberculosis
Latent tuberculosis infection
Interferon-gamma release assay
QuantiFERON-TB Gold In Tube
QuantiFERON-TB Gold Plus
MYCOBACTERIUM-TUBERCULOSIS INFECTION
INTERFERON-GAMMA ASSAYS
TB-GOLD
TUBE ASSAY
SKIN-TEST
PERFORMANCE
SENSITIVITY
CD4

Access to Document

10.1016/j.tube.2017.11.014Licence: CC BY-NC-ND

Cite this

Pieterman, E. D., Lung, F. G. L., Verbon, A., Bax, H. I., Ang, C. W., Berkhout, J., Blaauw, G., Brandenburg, A., van Burgel, N. D., Claessen, A., van Dijk, K., Heron, M., Hooghiemstra, M., Leussenkamp-Hummelink, R., van Lochem, E., van Loo, I. H. M., Mulder, B., Ott, A., Pontesilli, O., ... de Steenwinkel, J. E. M. (2018). A multicentre verification study of the QuantiFERON (R)-TB Gold Plus assay. Tuberculosis, 108, 136-142. https://doi.org/10.1016/j.tube.2017.11.014

@article{8e3ddc35f71a46619d17a1520ef4820d,

title = "A multicentre verification study of the QuantiFERON (R)-TB Gold Plus assay",

abstract = "Objectives: The aim of this verification study was to compare the QuantiFERON (R)-TB Gold Plus (QFT-Plus) to the QuantiFERON (R)-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8(+) T-cell response above the CD4(+) T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods: Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of > 0.6 IU/mL interferon-gamma release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8(+) T-cell response. Results: Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-gamma release compared to all other subjects (p = 0.029). Conclusion: Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-gamma release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.",

keywords = "Tuberculosis, Latent tuberculosis infection, Interferon-gamma release assay, QuantiFERON-TB Gold In Tube, QuantiFERON-TB Gold Plus, MYCOBACTERIUM-TUBERCULOSIS INFECTION, INTERFERON-GAMMA ASSAYS, TB-GOLD, TUBE ASSAY, SKIN-TEST, PERFORMANCE, SENSITIVITY, CD4",

author = "Pieterman, {E. D.} and Lung, {F. G. Liqui} and A. Verbon and Bax, {H. I.} and Ang, {C. W.} and J. Berkhout and G. Blaauw and A. Brandenburg and {van Burgel}, {N. D.} and A. Claessen and {van Dijk}, K. and M. Heron and M. Hooghiemstra and R. Leussenkamp-Hummelink and {van Lochem}, E. and {van Loo}, {I. H. M.} and B. Mulder and A. Ott and O. Pontesilli and A. Reuwer and P. Rombouts and V. Saegeman and M. Scholing and S. Vainio and {de Steenwinkel}, {J. E. M.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/j.tube.2017.11.014",

language = "English",

volume = "108",

pages = "136--142",

journal = "Tuberculosis",

issn = "1472-9792",

publisher = "Churchill Livingstone",

}

Pieterman, ED, Lung, FGL, Verbon, A, Bax, HI, Ang, CW, Berkhout, J, Blaauw, G, Brandenburg, A, van Burgel, ND, Claessen, A, van Dijk, K, Heron, M, Hooghiemstra, M, Leussenkamp-Hummelink, R, van Lochem, E, van Loo, IHM, Mulder, B, Ott, A, Pontesilli, O, Reuwer, A, Rombouts, P, Saegeman, V, Scholing, M, Vainio, S & de Steenwinkel, JEM 2018, 'A multicentre verification study of the QuantiFERON (R)-TB Gold Plus assay', Tuberculosis, vol. 108, pp. 136-142. https://doi.org/10.1016/j.tube.2017.11.014

TY - JOUR

T1 - A multicentre verification study of the QuantiFERON (R)-TB Gold Plus assay

AU - Pieterman, E. D.

AU - Lung, F. G. Liqui

AU - Verbon, A.

AU - Bax, H. I.

AU - Ang, C. W.

AU - Berkhout, J.

AU - Blaauw, G.

AU - Brandenburg, A.

AU - van Burgel, N. D.

AU - Claessen, A.

AU - van Dijk, K.

AU - Heron, M.

AU - Hooghiemstra, M.

AU - Leussenkamp-Hummelink, R.

AU - van Lochem, E.

AU - van Loo, I. H. M.

AU - Mulder, B.

AU - Ott, A.

AU - Pontesilli, O.

AU - Reuwer, A.

AU - Rombouts, P.

AU - Saegeman, V.

AU - Scholing, M.

AU - Vainio, S.

AU - de Steenwinkel, J. E. M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: The aim of this verification study was to compare the QuantiFERON (R)-TB Gold Plus (QFT-Plus) to the QuantiFERON (R)-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8(+) T-cell response above the CD4(+) T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods: Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of > 0.6 IU/mL interferon-gamma release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8(+) T-cell response. Results: Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-gamma release compared to all other subjects (p = 0.029). Conclusion: Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-gamma release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.

AB - Objectives: The aim of this verification study was to compare the QuantiFERON (R)-TB Gold Plus (QFT-Plus) to the QuantiFERON (R)-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8(+) T-cell response above the CD4(+) T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods: Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of > 0.6 IU/mL interferon-gamma release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8(+) T-cell response. Results: Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-gamma release compared to all other subjects (p = 0.029). Conclusion: Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-gamma release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.

KW - Tuberculosis

KW - Latent tuberculosis infection

KW - Interferon-gamma release assay

KW - QuantiFERON-TB Gold In Tube

KW - QuantiFERON-TB Gold Plus

KW - MYCOBACTERIUM-TUBERCULOSIS INFECTION

KW - INTERFERON-GAMMA ASSAYS

KW - TB-GOLD

KW - TUBE ASSAY

KW - SKIN-TEST

KW - PERFORMANCE

KW - SENSITIVITY

KW - CD4

U2 - 10.1016/j.tube.2017.11.014

DO - 10.1016/j.tube.2017.11.014

M3 - Article

C2 - 29523314

SN - 1472-9792

VL - 108

SP - 136

EP - 142

JO - Tuberculosis

JF - Tuberculosis

ER -